METTL3 and breast carcinoma: In breast cancer cell lines MCF-7 and MDA-MB-231, METTL3 augments resistance to doxorubicin (ADR) by improving the efficiency of HR and alleviating ADR-induced DNA damage.546 In MCF-7 cells that have developed resistance to ADR, the expression level of METTL3 is elevated.